Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens

Alterations in brain serotonergic function have been implicated in the mechanism of action of LSD, mescaline, and other similarly acting hallucinogenic drugs of abuse such as STP (2,5-dimethoxyphenylisopropylamine; DOM). In order to test the hypothesis that the mechanism of action of LSD and phenyli...

Full description

Saved in:
Bibliographic Details
Published inPsychopharmacology Vol. 94; no. 2; p. 213
Main Authors Titeler, M, Lyon, R A, Glennon, R A
Format Journal Article
LanguageEnglish
Published Germany 01.02.1988
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Alterations in brain serotonergic function have been implicated in the mechanism of action of LSD, mescaline, and other similarly acting hallucinogenic drugs of abuse such as STP (2,5-dimethoxyphenylisopropylamine; DOM). In order to test the hypothesis that the mechanism of action of LSD and phenylisopropylamine hallucinogens is through stimulation of a specific brain serotonin receptor sub-type, the affinities of these compounds for radiolabelled 5-HT2, 5-HT1A, 5-HT1B, and 5-HT1C receptors have been determined using recently developed in vitro radioligand binding methodologies. The 5-HT2 receptor was labelled with the agonist/hallucinogen radioligand 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine). The 5-HT1A, 5-HT1B, and 5-HT1C receptors were labelled with 3H-OH-DPAT, 3H-5-HT, and 3H-mesulergine, respectively. In general, the phenylisopropylamines displayed 10-100 fold higher affinities for the 5-HT2 receptor than for the 5-HT1C receptor and 100-1000 fold higher affinities for the 5-HT2 receptor than for the 5-HT1A or 5-HT1B receptor. There was a strong correlation between hallucinogenic potencies and 5-HT2 receptor affinities of the phenylisopropylamines (r = 0.90); the correlation coefficients for the 5-HT1A, 5-HT1B, and 5-HT1C were 0.73, 0.85, and 0.78, respectively. Because there is no evidence that 5-HT1A-selective or 5-HT1B-selective agonists are hallucinogenic and because the phenylisopropylamines are potent hallucinogens, a 5-HT2 receptor interaction is implicated and supports our previous suggestions to this effect. A secondary role for 5-HT1C receptors cannot be discounted at this time.
AbstractList Alterations in brain serotonergic function have been implicated in the mechanism of action of LSD, mescaline, and other similarly acting hallucinogenic drugs of abuse such as STP (2,5-dimethoxyphenylisopropylamine; DOM). In order to test the hypothesis that the mechanism of action of LSD and phenylisopropylamine hallucinogens is through stimulation of a specific brain serotonin receptor sub-type, the affinities of these compounds for radiolabelled 5-HT2, 5-HT1A, 5-HT1B, and 5-HT1C receptors have been determined using recently developed in vitro radioligand binding methodologies. The 5-HT2 receptor was labelled with the agonist/hallucinogen radioligand 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine). The 5-HT1A, 5-HT1B, and 5-HT1C receptors were labelled with 3H-OH-DPAT, 3H-5-HT, and 3H-mesulergine, respectively. In general, the phenylisopropylamines displayed 10-100 fold higher affinities for the 5-HT2 receptor than for the 5-HT1C receptor and 100-1000 fold higher affinities for the 5-HT2 receptor than for the 5-HT1A or 5-HT1B receptor. There was a strong correlation between hallucinogenic potencies and 5-HT2 receptor affinities of the phenylisopropylamines (r = 0.90); the correlation coefficients for the 5-HT1A, 5-HT1B, and 5-HT1C were 0.73, 0.85, and 0.78, respectively. Because there is no evidence that 5-HT1A-selective or 5-HT1B-selective agonists are hallucinogenic and because the phenylisopropylamines are potent hallucinogens, a 5-HT2 receptor interaction is implicated and supports our previous suggestions to this effect. A secondary role for 5-HT1C receptors cannot be discounted at this time.
Author Lyon, R A
Titeler, M
Glennon, R A
Author_xml – sequence: 1
  givenname: M
  surname: Titeler
  fullname: Titeler, M
  organization: Department of Pharmacology and Toxicology, Albany Medical College, NY 12208
– sequence: 2
  givenname: R A
  surname: Lyon
  fullname: Lyon, R A
– sequence: 3
  givenname: R A
  surname: Glennon
  fullname: Glennon, R A
BackLink https://www.ncbi.nlm.nih.gov/pubmed/3127847$$D View this record in MEDLINE/PubMed
BookMark eNotkE1LAzEURbOo1La6cS-8PzD6kkwz06XUjwoFQeu6vEnetJGZZJhMha7941bs3Vy4HM7iTsUoxMBC3Ei8k4jFfVUjysKUeTESE0StMy3n5aWYpvSFp-RlPhZjLVVxQibi552cj43fUXBQ-eB82AF_e8fBMvi2a7ylgRMMe4aqJx9gnq02Cnq23A2xB0pAkPzAEGsgO_gYoD7t649H-JN2ew7HxqfY9bE7NtT6wLCnpjlYH-KOQ7oSFzU1ia_PPROfz0-b5Spbv728Lh_Wmc1lOWS6rrRdVIiEeeHI4KKUZBfOGu0qdro2pEypnXFKOZbsTKEtotFWFVjnczUTt__e7lC17LZd71vqj9vzGeoXM-JiMQ
CitedBy_id crossref_primary_10_1016_j_neuropharm_2015_08_034
crossref_primary_10_1016_S0149_7634_99_00037_8
crossref_primary_10_1007_BF00451682
crossref_primary_10_1038_s41467_023_44016_1
crossref_primary_10_1111_j_1600_0773_1989_tb00623_x
crossref_primary_10_1016_j_bbagen_2009_06_009
crossref_primary_10_1038_sj_npp_1301600
crossref_primary_10_1016_0014_2999_89_90178_7
crossref_primary_10_1124_pharmrev_120_000056
crossref_primary_10_1016_S0006_8993_99_01224_X
crossref_primary_10_1016_S0091_3057_96_00469_8
crossref_primary_10_1016_S0149_7634_05_80054_5
crossref_primary_10_1007_s00213_008_1247_z
crossref_primary_10_3390_molecules29050964
crossref_primary_10_1016_0091_3057_92_90488_2
crossref_primary_10_1007_s00213_004_2108_z
crossref_primary_10_1111_j_1476_5381_1990_tb14138_x
crossref_primary_10_1046_j_1460_9568_1999_00708_x
crossref_primary_10_1016_j_pharmthera_2007_06_007
crossref_primary_10_1016_S0091_3057_01_00720_1
crossref_primary_10_1021_cr078224o
crossref_primary_10_1038_s41573_022_00421_7
crossref_primary_10_1007_s00204_015_1513_x
crossref_primary_10_1124_mol_109_059204
crossref_primary_10_1016_j_bbrc_2013_11_104
crossref_primary_10_1016_0024_3205_91_90603_9
crossref_primary_10_1016_j_cell_2017_01_012
crossref_primary_10_1016_S0006_8993_01_02596_3
crossref_primary_10_1038_s41583_020_0367_2
crossref_primary_10_1007_s00213_006_0566_1
crossref_primary_10_1016_j_neuint_2010_01_010
crossref_primary_10_1016_j_pbb_2007_06_001
crossref_primary_10_1016_0091_3057_94_90077_9
crossref_primary_10_1016_S0278_5846_98_00031_1
crossref_primary_10_1007_BF02245187
crossref_primary_10_1523_JNEUROSCI_17_08_02785_1997
crossref_primary_10_1016_0091_3057_93_90120_I
crossref_primary_10_1089_adt_2016_747
crossref_primary_10_1016_j_neuroimage_2019_06_053
crossref_primary_10_1016_0091_3057_92_90403_3
crossref_primary_10_1016_j_pbb_2005_05_011
crossref_primary_10_1016_j_euroneuro_2016_05_001
crossref_primary_10_1007_BF02244428
crossref_primary_10_1038_sj_bjp_0707473
crossref_primary_10_1111_j_1530_0277_1993_tb00785_x
crossref_primary_10_1007_s00213_024_06635_4
crossref_primary_10_1007_BF00451678
crossref_primary_10_1016_0091_3057_89_90470_X
crossref_primary_10_1016_S0091_3057_01_00767_5
crossref_primary_10_1038_sj_npp_1300711
crossref_primary_10_1177_026988118700100402
crossref_primary_10_1007_BF02247372
crossref_primary_10_1002_ddr_430160227
crossref_primary_10_1007_s12640_020_00297_8
crossref_primary_10_1007_BF02245809
crossref_primary_10_3928_0048_5713_19940301_09
crossref_primary_10_1016_S0361_9230_01_00646_3
crossref_primary_10_1007_s00213_011_2616_6
crossref_primary_10_1016_0040_4039_96_01807_2
crossref_primary_10_1007_s00213_005_0245_7
crossref_primary_10_1002_syn_890130205
crossref_primary_10_1016_0163_1047_91_80140_A
crossref_primary_10_1002__SICI_1096_9861_19990628_409_2_187__AID_CNE2_3_0_CO_2_P
crossref_primary_10_1111_j_1749_6632_1990_tb16914_x
crossref_primary_10_1016_0306_3623_94_90035_3
crossref_primary_10_1016_0091_3057_90_90228_A
crossref_primary_10_15436_2377_0902_17_1629
crossref_primary_10_1016_j_bcp_2007_07_018
crossref_primary_10_1021_jm9705925
crossref_primary_10_1007_BF02244609
crossref_primary_10_1016_0091_3057_91_90121_H
crossref_primary_10_1016_S0006_3223_03_00236_1
crossref_primary_10_1016_0024_3205_88_90342_6
crossref_primary_10_1016_j_bbr_2014_07_016
crossref_primary_10_1021_jm970219x
crossref_primary_10_1016_0091_3057_90_90047_L
crossref_primary_10_3390_ijms23126713
crossref_primary_10_1016_0091_3057_92_90406_6
crossref_primary_10_1007_s00213_006_0358_7
crossref_primary_10_1016_j_neuropharm_2004_06_026
crossref_primary_10_1016_j_pharmthera_2003_11_002
crossref_primary_10_1007_BF02244617
crossref_primary_10_1016_S0091_3057_03_00159_X
crossref_primary_10_1016_j_bbrc_2020_08_022
crossref_primary_10_1016_0091_3057_90_90098_3
crossref_primary_10_1016_j_patter_2023_100865
crossref_primary_10_1016_j_cell_2016_12_033
crossref_primary_10_3390_molecules28176236
crossref_primary_10_3389_fnhum_2017_00245
crossref_primary_10_1124_pr_110_003244
crossref_primary_10_1016_S0166_4328_97_02315_2
crossref_primary_10_1016_S0166_4328_03_00179_7
crossref_primary_10_1007_BF02245940
crossref_primary_10_1021_acsptsci_2c00177
crossref_primary_10_1016_0028_3908_95_00101_B
crossref_primary_10_1016_0166_6851_91_90097_P
crossref_primary_10_1016_S0006_3223_98_00036_5
crossref_primary_10_3390_ijms25010241
crossref_primary_10_1007_s00213_012_2891_x
crossref_primary_10_1016_j_pharmthera_2011_10_007
crossref_primary_10_1016_j_bbr_2004_04_026
crossref_primary_10_1016_0028_3908_90_90151_G
crossref_primary_10_1007_s00213_009_1718_x
crossref_primary_10_1093_ijnp_pyy047
crossref_primary_10_1016_0014_2999_91_90675_G
crossref_primary_10_1248_yakushi_128_1771
crossref_primary_10_1016_0091_3057_94_90542_8
crossref_primary_10_1007_BF00167563
crossref_primary_10_1007_BF00167564
crossref_primary_10_2139_ssrn_4072041
crossref_primary_10_1016_0014_2999_91_90106_Z
crossref_primary_10_1111_j_1600_0773_1990_tb01604_x
crossref_primary_10_1016_0014_2999_94_90690_4
crossref_primary_10_1002_dta_2245
crossref_primary_10_1016_S0306_4522_01_00170_1
crossref_primary_10_29328_journal_jnnd_1001078
crossref_primary_10_1016_j_neuropharm_2003_08_004
crossref_primary_10_1111_adb_12926
crossref_primary_10_1177_026988119500900107
crossref_primary_10_1016_j_biopsych_2014_11_015
crossref_primary_10_1124_jpet_118_251199
crossref_primary_10_2147_NDT_S371641
crossref_primary_10_1007_BF02245219
crossref_primary_10_1007_s00210_024_02983_2
crossref_primary_10_1016_j_jmgm_2012_06_006
crossref_primary_10_3390_metabo11040212
crossref_primary_10_1038_sj_bjp_0702751
crossref_primary_10_1016_j_pharmthera_2022_108195
crossref_primary_10_1021_jm960199j
crossref_primary_10_1002_dta_3668
crossref_primary_10_1016_0163_7258_94_90051_5
crossref_primary_10_1016_j_euroneuro_2014_04_009
crossref_primary_10_1046_j_1460_9568_2003_02829_x
crossref_primary_10_1016_0006_8993_90_91199_Q
crossref_primary_10_1016_0006_3223_95_00200_6
crossref_primary_10_1111_j_1755_5949_2008_00059_x
crossref_primary_10_1007_BF02244372
crossref_primary_10_1002_syn_21835
crossref_primary_10_1016_S0166_4328_00_00378_8
crossref_primary_10_1007_s40263_020_00752_2
crossref_primary_10_1007_s43440_023_00550_9
crossref_primary_10_1021_jm000339w
crossref_primary_10_1021_ol0510522
crossref_primary_10_1007_BF02316866
crossref_primary_10_1016_S0278_5846_98_00024_4
crossref_primary_10_1016_S0040_4039_00_82391_6
crossref_primary_10_1034_j_1600_0773_2003_920504_x
crossref_primary_10_14814_phy2_12003
crossref_primary_10_1021_acschemneuro_0c00129
crossref_primary_10_1002_syn_890050409
crossref_primary_10_1111_j_1360_0443_1994_tb03330_x
crossref_primary_10_1073_pnas_0700436104
crossref_primary_10_1002_hlca_200390224
crossref_primary_10_1046_j_1468_2982_1993_1302075_x
crossref_primary_10_1016_j_bmcl_2004_07_081
crossref_primary_10_3389_fnmol_2021_790213
crossref_primary_10_1016_S0091_3057_99_00178_1
crossref_primary_10_3389_fphar_2024_1334218
crossref_primary_10_1038_jcbfm_1995_99
crossref_primary_10_1002_ejoc_202200315
crossref_primary_10_1016_S0028_3908_99_00159_8
crossref_primary_10_3389_fnins_2020_00078
crossref_primary_10_1007_BF02253718
crossref_primary_10_1007_s00210_023_02414_8
crossref_primary_10_1016_S0091_3057_00_00241_0
crossref_primary_10_1016_S0006_2952_97_00405_X
crossref_primary_10_3928_0048_5713_19930401_07
crossref_primary_10_1007_s00213_013_3303_6
crossref_primary_10_1016_j_ejphar_2019_05_014
crossref_primary_10_1016_j_neuropharm_2013_01_014
crossref_primary_10_1007_BF00441948
crossref_primary_10_1038_npp_2009_29
crossref_primary_10_1152_ajpcell_00397_2022
crossref_primary_10_1016_j_neuropharm_2011_01_012
crossref_primary_10_1016_j_bbr_2005_07_013
crossref_primary_10_1016_0361_9230_90_90194_5
crossref_primary_10_1016_j_neuropharm_2011_01_017
crossref_primary_10_1016_0091_3057_94_90172_4
crossref_primary_10_1016_S0969_8051_02_00306_2
crossref_primary_10_1016_S0149_7634_05_80158_7
crossref_primary_10_1016_0924_977X_95_00027_M
crossref_primary_10_1016_0006_3223_93_90204_Q
crossref_primary_10_1016_S0091_3057_01_00552_4
crossref_primary_10_7554_eLife_31991
crossref_primary_10_1016_0014_2999_96_00325_1
crossref_primary_10_1007_s40265_016_0600_5
crossref_primary_10_1016_S0306_4522_98_00043_8
crossref_primary_10_1016_j_biopha_2023_115775
crossref_primary_10_3390_molecules26092451
crossref_primary_10_1177_0269881106059583
crossref_primary_10_1016_S0091_3057_97_00527_3
crossref_primary_10_1016_S0376_8716_98_00076_3
crossref_primary_10_1177_0269881120959604
crossref_primary_10_1007_BF02246075
crossref_primary_10_1007_BF02246076
crossref_primary_10_4155_fmc_10_261
crossref_primary_10_1007_BF00168596
crossref_primary_10_1007_BF02246074
crossref_primary_10_1021_jm048963m
crossref_primary_10_1021_ol034228d
crossref_primary_10_1002_syn_20141
crossref_primary_10_1016_j_neuropharm_2017_07_012
crossref_primary_10_1021_acs_jmedchem_7b00085
crossref_primary_10_1093_ijnp_pyv072
crossref_primary_10_1007_BF02247721
crossref_primary_10_1021_acsptsci_2c00222
crossref_primary_10_1177_0269881105056660
crossref_primary_10_1152_physiolgenomics_00125_2003
crossref_primary_10_1111_bcp_14115
crossref_primary_10_1007_BF00442251
crossref_primary_10_1016_0014_2999_95_00279_T
crossref_primary_10_3390_ijms21239279
crossref_primary_10_1016_S0169_328X_03_00029_9
crossref_primary_10_1007_s00213_004_2130_1
crossref_primary_10_1016_S0149_7634_03_00031_9
crossref_primary_10_1016_0166_4328_96_00102_7
crossref_primary_10_1016_j_euroneuro_2014_05_008
crossref_primary_10_3389_fendo_2014_00071
crossref_primary_10_1016_j_euroneuro_2022_09_004
crossref_primary_10_1517_13543784_2013_769957
crossref_primary_10_1016_S0165_0173_00_00026_6
crossref_primary_10_1007_BF02244228
crossref_primary_10_1007_BF02246643
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1007/bf00176847
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
ExternalDocumentID 3127847
Genre Research Support, U.S. Gov't, P.H.S
Journal Article
GrantInformation_xml – fundername: NIMH NIH HHS
  grantid: MH40716-01A2
GroupedDBID -4W
-BR
.55
3SX
40D
40E
95.
95~
ABMNI
AGWIL
ALMA_UNASSIGNED_HOLDINGS
CGR
CUY
CVF
ECM
EIF
KOW
N2Q
NPM
R9-
RHV
SBY
SOJ
X7M
~EX
ID FETCH-LOGICAL-c418t-3fb3c9b00a047da60981ac9dc63dbed3f6a2683d6d22de1ed673c0063c270f452
ISSN 0033-3158
IngestDate Sat Nov 02 12:12:41 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c418t-3fb3c9b00a047da60981ac9dc63dbed3f6a2683d6d22de1ed673c0063c270f452
PMID 3127847
ParticipantIDs pubmed_primary_3127847
PublicationCentury 1900
PublicationDate 1988-02-00
PublicationDateYYYYMMDD 1988-02-01
PublicationDate_xml – month: 02
  year: 1988
  text: 1988-02-00
PublicationDecade 1980
PublicationPlace Germany
PublicationPlace_xml – name: Germany
PublicationTitle Psychopharmacology
PublicationTitleAlternate Psychopharmacology (Berl)
PublicationYear 1988
SSID ssj0000484
ssj0068394
Score 1.7758651
Snippet Alterations in brain serotonergic function have been implicated in the mechanism of action of LSD, mescaline, and other similarly acting hallucinogenic drugs...
SourceID pubmed
SourceType Index Database
StartPage 213
SubjectTerms Amphetamines - pharmacology
Animals
Behavior, Animal - drug effects
Brain - drug effects
Brain - metabolism
DOM 2,5-Dimethoxy-4-Methylamphetamine - analogs & derivatives
DOM 2,5-Dimethoxy-4-Methylamphetamine - pharmacology
Hallucinogens - metabolism
Hallucinogens - pharmacology
In Vitro Techniques
Lysergic Acid Diethylamide - pharmacology
Male
Radioligand Assay
Rats
Rats, Inbred Strains
Receptors, Serotonin - drug effects
Receptors, Serotonin - metabolism
Title Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens
URI https://www.ncbi.nlm.nih.gov/pubmed/3127847
Volume 94
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF6clpZcSps29M0cSi6OirSSVtKx9GVKEkKrQG5hX2oFqS2Qc3Cu-eOd0a4lObj0cRH2LqxlfR-zs6P5Zhh7IxIZFcZSeMkoPKBoG0hb6cCiKyK01GkWkhr5-ETMzpIv5-n5ZHI1Vpcs1Vt9vVVX8j-o4hjiSirZf0C2XxQH8DPii1dEGK9_hfFXaerFZf2dgt-qdvoU69uEkv7RCdzazrlU1Atimgazkk_RytlmSemT7VRO6f1xlw6g-7zDo28fXAWBH3a-uqzbBdrZZoXkIZ-U2q9c6Xq-wPtqx86tM6bNUAy7D9eX-BNecthHeo5WXto_hFM_4xY43xw1TqGHkIR9coc3sjFJ9lxF9rWRdZ2MPZn4hsWMt1pyl7yhKtpGRe6qco4gbX52mMYRvTj98-Stmtp-ZoftZDkZxxMK8ay374SUu-6LQPfR1fH2f2lU4Ha4tV12zy9462zS-SjlQ_bAHy7gnWPKIzax8z12_9inT-yxg1OHzeoQykF31x7CAZyOUHvMbkbMAs8sWDMLBmYBMgs6ZkHHLFgzC2QLEohZsKjAMQuQWYDMAlp0G7Ngg1lP2Nmnj-X7WeDbdQQ6ifJlEFcq1lRiU4ZJZqQIizySujBaxEZZE1dCcnygRhjOjY2sEVmsyUXWPAurJOX77A5yzD5loDOT5GmlOJUOUnGhKpUqzYtQcsnxSPyM7bvnfNG4miwXHoDnv5t4wXYHrr5kdys0AfYV-pNL9brD_xeAJ3dy
link.rule.ids 783
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Radioligand+binding+evidence+implicates+the+brain+5-HT2+receptor+as+a+site+of+action+for+LSD+and+phenylisopropylamine+hallucinogens&rft.jtitle=Psychopharmacology&rft.au=Titeler%2C+M&rft.au=Lyon%2C+R+A&rft.au=Glennon%2C+R+A&rft.date=1988-02-01&rft.issn=0033-3158&rft.volume=94&rft.issue=2&rft.spage=213&rft_id=info:doi/10.1007%2Fbf00176847&rft_id=info%3Apmid%2F3127847&rft_id=info%3Apmid%2F3127847&rft.externalDocID=3127847
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon